{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:32:39Z","timestamp":1790728359847,"version":"4.1.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Survival in cancer is continuously improving due to evolving oncological treatment. Therefore, cardiovascular short-term and long-term side effects gain crucial importance for overall outcome. Cardiotoxicity not only presents as heart failure, but also as treatment-resistant hypertension, acute coronary ischemia with plaque rupture or vasospasm, thromboembolism, arrhythmia, pulmonary hypertension, diastolic dysfunction, acute myocarditis and others. Recent recommendations have proposed baseline cardiac risk assessment and surveillance strategies. Major challenges are the availability of monitoring and imaging resources, including echocardiography with speckle tracking longitudinal strain (GLS), serum biomarkers such as natriuretic peptides (NT-proBNP) and highly sensitive cardiac troponins. This Austrian consensus encompasses cardiotoxicity occurrence in frequent antiproliferative cancer drugs, radiotherapy, immune checkpoint inhibitors and cardiac follow-up considerations in cancer survivors in the context of the Austrian healthcare setting. It is important to optimize cardiovascular risk factors and pre-existing cardiac diseases without delaying oncological treatment. If left ventricular ejection fraction (LVEF) deteriorates during cancer treatment (from &gt;10% to &lt;50%), or myocardial strain decreases (&gt;15% change in GLS), early initiation of cardioprotective therapies (angiotensin-converting enzyme inhibitors, angiotensin or beta receptor blockers) is recommended, and LVEF should be reassessed before discontinuation. Lower LVEF cut-offs were recently shown to be feasible in breast cancer patients to enable optimal anticancer treatment. Interdisciplinary cardio-oncology cooperation is pivotal for optimal management of cancer patients.<\/jats:p>","DOI":"10.1007\/s00508-022-02031-0","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T06:03:24Z","timestamp":1651644204000},"page":"654-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies"],"prefix":"10.1007","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-1380","authenticated-orcid":false,"given":"Jutta","family":"Bergler-Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Michael","family":"Zaruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"D\u00f6rler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Buchacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Adlbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Gy\u00f6ngy\u00f6si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula-Maria","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"issue":"25","key":"2031_CR1","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMra1712502","volume":"379","author":"CL Shapiro","year":"2018","unstructured":"Shapiro\u00a0CL. Cancer survivorship. N\u00a0Engl J Med. 2018;379(25):2438\u201350.","journal-title":"N Engl J Med"},{"issue":"36","key":"2031_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano\u00a0JL, Lancellotti\u00a0P, Rodriguez Mu\u00f1oz\u00a0D, Aboyans\u00a0V, Asteggiano\u00a0R, Galderisi\u00a0M, et\u00a0al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart\u00a0J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"issue":"10","key":"2031_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana\u00a0JC, Galderisi\u00a0M, Barac\u00a0A, Ewer\u00a0MS, Ky\u00a0B, Scherrer-Crosbie\u00a0M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a\u00a0report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063\u201393.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"2031_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ehjci\/jeaa111","volume":"22","author":"I Stankovic","year":"2021","unstructured":"Stankovic\u00a0I, Dweck\u00a0MR, Marsan\u00a0NA, Bergler-Klein\u00a0J, Holte\u00a0E, Manka\u00a0R, et al. The EACVI survey on cardiac imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021;22(4):367\u201371.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"2031_CR5","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","volume":"22","author":"RA de Boer","year":"2020","unstructured":"de Boer\u00a0RA, Hulot\u00a0JS, Tocchetti\u00a0CG, Aboumsallem\u00a0JP, Ameri\u00a0P, Anker\u00a0SD, et\u00a0al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the translational research committee of the heart failure association (HFA) of the European society of cardiology (ESC). Eur J Heart Fail. 2020;22(12):2272\u201389.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"2031_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117\u00a0J, Pudil\u00a0R, L\u00f3pez-Fern\u00e1ndez\u00a0T, Grapsa\u00a0J, Nihoyannopoulos\u00a0P, Bergler-Klein\u00a0J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a\u00a0position statement on behalf of the heart failure association (HFA), the European association of cardiovascular imaging (EACVI) and the cardio-oncology council of the European society of cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504\u201324.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"2031_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J L\u00f3pez-Send\u00f3n","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n\u00a0J, \u00c1lvarez-Ortega\u00a0C, Zamora Au\u00f1on\u00a0P, Bu\u00f1o Soto\u00a0A, Lyon\u00a0AR, Farmakis\u00a0D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart\u00a0J. 2020;41(18):1720\u20139.","journal-title":"Eur Heart J"},{"issue":"11","key":"2031_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil\u00a0R, Mueller\u00a0C, \u010celutkien\u0117\u00a0J, Henriksen\u00a0PA, Lenihan\u00a0D, Dent\u00a0S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a\u00a0position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the European society of cardiology. Eur J Heart Fail. 2020;22(11):1966\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2031_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen\u00a0PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971\u20137.","journal-title":"Heart"},{"issue":"1","key":"2031_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa\u00a0P, Yeh\u00a0ET. Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"2031_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","volume":"7","author":"A Murabito","year":"2020","unstructured":"Murabito\u00a0A, Hirsch\u00a0E, Ghigo\u00a0A. Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer? Front Cardiovasc Med. 2020;7:35.","journal-title":"Front Cardiovasc Med"},{"key":"2031_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale\u00a0D, Iacopo\u00a0F, Cipolla\u00a0CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2031_CR13","first-page":"970","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2020","unstructured":"Gy\u00f6ngy\u00f6si\u00a0M, Lukovic\u00a0D, Zlabinger\u00a0K, Spannbauer\u00a0A, Gugerell\u00a0A, Pavo\u00a0N, et al. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovasc Res. 2020;116(5):970\u201382.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2031_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10555-020-09859-w","volume":"39","author":"N Bansal","year":"2020","unstructured":"Bansal\u00a0N, Blanco\u00a0JG, Sharma\u00a0UC, Pokharel\u00a0S, Shisler\u00a0S, Lipshultz\u00a0SE. Cardiovascular diseases in survivors of childhood cancer. Cancer Metastasis Rev. 2020;39(1):55\u201368.","journal-title":"Cancer Metastasis Rev"},{"key":"2031_CR15","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain\u00a0SM, Whaley\u00a0FS, Ewer\u00a0MS. Congestive heart failure in patients treated with doxorubicin: a\u00a0retrospective analysis of three trials. Cancer. 2003;97:2869\u201379.","journal-title":"Cancer"},{"issue":"9","key":"2031_CR16","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon\u00a0AR, Yousaf\u00a0N, Battisti\u00a0NML, Moslehi\u00a0J, Larkin\u00a0J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u2013e4.","journal-title":"Lancet Oncol"},{"issue":"15","key":"2031_CR17","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi\u00a0JJ. Cardiovascular toxic effects of targeted cancer therapies. N\u00a0Engl J Med. 2016;375(15):1457\u201367.","journal-title":"N Engl J Med"},{"issue":"15","key":"2031_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter\u00a0TM, Ewer\u00a0MS. Cancer drugs and the heart: importance and management. Eur Heart\u00a0J. 2013;34(15):1102\u201311.","journal-title":"Eur Heart J"},{"issue":"24","key":"2031_CR19","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh\u00a0ET, Bickford\u00a0CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J\u00a0Am Coll Cardiol. 2009;53(24):2231\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2031_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon\u00a0AR, Dent\u00a0S, Stanway\u00a0S, Earl\u00a0H, Brezden-Masley\u00a0C, Cohen-Solal\u00a0A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a\u00a0position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"2031_CR21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale\u00a0D, Colombo\u00a0A, Bacchiani\u00a0G, Tedeschi\u00a0I, Meroni\u00a0CA, Veglia\u00a0F, et\u00a0al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138.","journal-title":"Circulation"},{"key":"2031_CR22","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.ejca.2015.08.011","volume":"51","author":"E de Azambuja","year":"2015","unstructured":"de Azambuja\u00a0E, Ameye\u00a0L, Diaz\u00a0M, Vandenbossche\u00a0S, Aftimos\u00a0P, Bejarano Hernandez\u00a0S, et al. Cardiac assessment of early breast cancer patients 18\u00a0years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer. 2015;51:2517\u201324.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2031_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale\u00a0D, Colombo\u00a0A, Lamantia\u00a0G, Colombo\u00a0N, Civelli\u00a0M, De Giacomi\u00a0G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J\u00a0Am Coll Cardiol. 2010;55(3):213\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2031_CR24","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.3390\/cancers13174421","volume":"13","author":"F Schettini","year":"2021","unstructured":"Schettini\u00a0F, Giuliano\u00a0M, Lambertini\u00a0M, Bartsch\u00a0R, Pinato\u00a0DJ, Onesti\u00a0CE, et al. Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel). 2021;13(17):4421.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2031_CR25","first-page":"68","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo\u00a0AVS, Hajjar\u00a0LA, Lyon\u00a0AR, Nascimento\u00a0BR, Putzu\u00a0A, Rossi\u00a0L, et\u00a0al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. J\u00a0Am Coll Cardiol. 2019;1(1):68\u201379.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2031_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.15420\/cfr.2018.32.2","volume":"5","author":"A Cuomo","year":"2019","unstructured":"Cuomo\u00a0A, Rodolico\u00a0A, Galdieri\u00a0A, et\u00a0al. Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients. Card Fail Rev. 2019;5(2):112\u20138.","journal-title":"Card Fail Rev"},{"issue":"10087","key":"2031_CR27","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl\u00a0S, Gianni\u00a0L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u201329.","journal-title":"Lancet"},{"issue":"10075","key":"2031_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron\u00a0D, Piccart-Gebhart\u00a0MJ, Gelber\u00a0RD, Procter\u00a0M, Goldhirsch\u00a0A, de Azambuja\u00a0E, et al. 11\u00a0years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205.","journal-title":"Lancet"},{"issue":"27","key":"2031_CR29","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.20.00147","volume":"38","author":"C Saura","year":"2020","unstructured":"Saura\u00a0C, Oliveira\u00a0M, Feng\u00a0YH, Dai\u00a0MS, Chen\u00a0SW, Hurvitz\u00a0SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial. J\u00a0Clin Oncol. 2020;38(27):3138\u201349.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2031_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy\u00a0RK, Loi\u00a0S, Okines\u00a0A, Paplomata\u00a0E, Hamilton\u00a0E, Hurvitz\u00a0SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N\u00a0Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"key":"2031_CR31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/annonc\/annonc741","volume":"5","author":"J Cortes","year":"2021","unstructured":"Cortes\u00a0J, Kim\u00a0SB, Chung\u00a0WP, et\u00a0al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32(suppl_5):S1283\u2013346. https:\/\/doi.org\/10.1016\/annonc\/annonc741.","journal-title":"Ann Oncol"},{"key":"2031_CR32","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","volume":"367","author":"GM Cote","year":"2012","unstructured":"Cote\u00a0GM, Sawyer\u00a0DB, Chabner\u00a0BA. ERBB2 inhibition and heart failure. N\u00a0Engl J Med. 2012;367:2150\u20133.","journal-title":"N Engl J Med"},{"issue":"9","key":"2031_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jchf.2019.04.014","volume":"7","author":"S Goel","year":"2019","unstructured":"Goel\u00a0S, Liu\u00a0J, Guo\u00a0H, Barry\u00a0W, Bell\u00a0R, Murray\u00a0B, et\u00a0al. Decline in left ventricular ejection fraction following anthracyclines predicts trastuzumab cardiotoxicity. JACC Heart Fail. 2019;7(9):795\u2013804.","journal-title":"JACC Heart Fail"},{"key":"2031_CR34","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer\u00a0MS, Lippman\u00a0SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a\u00a0new entity. J\u00a0Clin Oncol. 2005;23:2900\u20132.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2031_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMp058315","volume":"354","author":"KR Chien","year":"2006","unstructured":"Chien\u00a0KR. Herceptin and the heart\u2014a\u00a0molecular modifier of cardiac failure. N\u00a0Engl J Med. 2006;354(8):789\u201390.","journal-title":"N Engl J Med"},{"key":"2031_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.yjmcc.2006.08.002","volume":"41","author":"F Timolati","year":"2006","unstructured":"Timolati\u00a0F, Ott\u00a0D, Pentassuglia\u00a0L, Giraud\u00a0M\u2011N, Perriard\u00a0J\u2011C, Suter\u00a0TM, et al. Neuregulin\u20111 beta attenuates doxorubicin-induced alterations of excitation contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J\u00a0Mol Cell Cardiol. 2006;41:845\u201354.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"2031_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey\u00a0N, Rosenthal\u00a0A, Dabas\u00a0N, Kropotova\u00a0Y, Lippman\u00a0M, Bishopric\u00a0NH. Trastuzumab-induced cardiotoxicity: a\u00a0review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2031_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano\u00a0G, Lenihan\u00a0D, Fradley\u00a0M, Ganatra\u00a0S, Barac\u00a0A, Blaes\u00a0A, et\u00a0al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"9897","key":"2031_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch\u00a0A, Gelber\u00a0RD, Piccart-Gebhart\u00a0MJ, de Azambuja\u00a0E, Procter\u00a0M, Suter\u00a0TM, et al. 2\u00a0years versus 1\u00a0year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021\u20138.","journal-title":"Lancet"},{"key":"2031_CR40","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja\u00a0E, Procter\u00a0MJ, van Veldhuisen\u00a0DJ, Agbor-Tarh\u00a0D, Metzger-Filho\u00a0O, Steinseifer\u00a0J, et al. Trastuzumab-associated cardiac events at 8\u00a0years of median follow-up in the herceptin adjuvant trial (BIG 1\u201101). J\u00a0Clin Oncol. 2014;32:2159\u201365.","journal-title":"J Clin Oncol"},{"key":"2031_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055","volume":"6","author":"S Seicean","year":"2013","unstructured":"Seicean\u00a0S, Seicean\u00a0A, Alan\u00a0N, Plana\u00a0JC, Budd\u00a0GT, Marwick\u00a0TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6:420\u20136.","journal-title":"Circ Heart Fail"},{"issue":"22","key":"2031_CR42","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin\u00a0M, Krischer\u00a0J, Tamura\u00a0R, Fink\u00a0A, Bello-Matricaria\u00a0L, McCaskill-Stevens\u00a0W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J\u00a0Am Coll Cardiol. 2019;73(22):2859\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2031_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ehjci\/jez194","volume":"20","author":"C Santoro","year":"2019","unstructured":"Santoro\u00a0C, Esposito\u00a0R, Lembo\u00a0M, Sorrentino\u00a0R, De Santo\u00a0I, Luciano\u00a0F, et al. Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 2019;20(12):1345\u201352.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"2031_CR44","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djaa054","volume":"112","author":"M Rushton","year":"2020","unstructured":"Rushton\u00a0M, Lima\u00a0I, Tuna\u00a0M, Johnson\u00a0C, Ivars\u00a0J, Pritchard\u00a0K, et al. Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada. J\u00a0Natl Cancer Inst. 2020;112(12):1222\u201330.","journal-title":"J Natl Cancer Inst"},{"key":"2031_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce\u00a0F, Barac\u00a0A, Geng\u00a0X, Dang\u00a0C, Yu\u00a0AF, Smith\u00a0KL, et al. Prospective evaluation oft he cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175:595\u2013603.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2031_CR46","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","volume":"185","author":"K Khoury","year":"2021","unstructured":"Khoury\u00a0K, Lynce\u00a0F, Barac\u00a0A, Geng\u00a0X, Dang\u00a0C, Yu\u00a0AF, et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a\u00a0clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat. 2021;185(3):863\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"2031_CR47","first-page":"1","volume":"1","author":"DP Leong","year":"2019","unstructured":"Leong\u00a0DP, Cosman\u00a0T, Alhussein\u00a0MM, Tyagi\u00a0NK, Karampatos\u00a0S, Barron\u00a0CC, et\u00a0al. Safety of continuing trastuzumab despite mild cardiotoxicity. J\u00a0Am Coll Cardiol. 2019;1:1\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2031_CR48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan\u00a0P, Negishi\u00a0T, Somerset\u00a0E, Negishi\u00a0K, Penicka\u00a0M, Lemieux\u00a0J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J\u00a0Am Coll Cardiol. 2021;77(4):392\u2013401.","journal-title":"J Am Coll Cardiol"},{"key":"2031_CR49","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart\u00a0M, Holmes\u00a0E, Baselga\u00a0J, de Azambuja\u00a0E, Dueck\u00a0AC, Viale\u00a0G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2\u2011positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J\u00a0Clin Oncol. 2016;34:1034\u201342.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2031_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","volume":"23","author":"SF Dent","year":"2021","unstructured":"Dent\u00a0SF, Morse\u00a0A, Burnette\u00a0S, Guha\u00a0A, Moore\u00a0H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep. 2021;23(11):128.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2031_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ehjci\/jeaa341","volume":"22","author":"MK Frey","year":"2021","unstructured":"Frey\u00a0MK, Bergler-Klein\u00a0J. Echocardiographic evaluation of patients undergoing cancer therapy. Eur Heart J Cardiovasc Imaging. 2021;22(4):375\u201382.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"19","key":"2031_CR52","doi-asserted-by":"publisher","first-page":"e017787","DOI":"10.1161\/JAHA.120.017787","volume":"9","author":"D Addison","year":"2020","unstructured":"Addison\u00a0D, Campbell\u00a0CM, Guha\u00a0A, Ghosh\u00a0AK, Dent\u00a0SF, Jneid\u00a0H. Cardio-oncology in the era of the COVID-19 pandemic and beyond. J\u00a0Am Heart Assoc. 2020;9(19):e17787.","journal-title":"J Am Heart Assoc"},{"issue":"36","key":"2031_CR53","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, Gardner\u00a0RS, Baumbach\u00a0A, B\u00f6hm\u00a0M, et\u00a0al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"25","key":"2031_CR54","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck\u00a0SL, Mecinaj\u00a0A, Ree\u00a0AH, Hoffmann\u00a0P, Schulz-Menger\u00a0J, Fagerland\u00a0MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a\u00a02\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143(25):2431\u201340.","journal-title":"Circulation"},{"key":"2031_CR55","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay\u00a0J, Colombet\u00a0M, Soerjomataram\u00a0I, Dyba\u00a0T, Randi\u00a0G, Bettio\u00a0M, et\u00a0al. Cancer incidence and mortality patterns in Europe: estimates for 40\u00a0countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2031_CR56","doi-asserted-by":"publisher","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","volume":"14","author":"TM Okwuosa","year":"2021","unstructured":"Okwuosa\u00a0TM, Morgans\u00a0A, Rhee\u00a0JW, Reding\u00a0KW, Maliski\u00a0S, Plana\u00a0JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American heart association. Circ Genom Precis Med. 2021;14(3):e82.","journal-title":"Circ Genom Precis Med"},{"issue":"8","key":"2031_CR57","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso\u00a0F, Kyriakides\u00a0S, Ohno\u00a0S, Penault-Llorca\u00a0F, Poortmans\u00a0P, Rubio\u00a0IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"issue":"4","key":"2031_CR58","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet\u00a0N, Bellmunt\u00a0J, Bolla\u00a0M, Briers\u00a0E, Cumberbatch\u00a0MG, De Santis\u00a0M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"issue":"9","key":"2031_CR59","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/cam4.767","volume":"5","author":"AS Quante","year":"2016","unstructured":"Quante\u00a0AS, Ming\u00a0C, Rottmann\u00a0M, Engel\u00a0J, Boeck\u00a0S, Heinemann\u00a0V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649\u201356.","journal-title":"Cancer Med"},{"issue":"11","key":"2031_CR60","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","volume":"18","author":"RS Braithwaite","year":"2003","unstructured":"Braithwaite\u00a0RS, Chlebowski\u00a0RT, Lau\u00a0J, George\u00a0S, Hess\u00a0R, Col\u00a0NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J\u00a0Gen Intern Med. 2003;18(11):937\u201347.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"2031_CR61","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","volume":"111","author":"A Decensi","year":"2005","unstructured":"Decensi\u00a0A, Maisonneuve\u00a0P, Rotmensz\u00a0N, Bettega\u00a0D, Costa\u00a0A, Sacchini\u00a0V, et\u00a0al. Effect of tamoxifen on venous thromboembolic events in a\u00a0breast cancer prevention trial. Circulation. 2005;111(5):650\u20136.","journal-title":"Circulation"},{"key":"2031_CR62","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2021.07.004","volume":"59","author":"M Sund","year":"2021","unstructured":"Sund\u00a0M, Garcia-Argibay\u00a0M, Garmo\u00a0H, Ahlgren\u00a0J, Wennstig\u00a0AK, Fredriksson\u00a0I, et al. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: a population-based cohort study. Breast. 2021;59:157\u201364.","journal-title":"Breast"},{"issue":"2","key":"2031_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor\u00a0E, Mosca\u00a0L, Collins\u00a0P, Geiger\u00a0MJ, Grady\u00a0D, Kornitzer\u00a0M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N\u00a0Engl J Med. 2006;355(2):125\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"2031_CR64","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/cncr.24219","volume":"115","author":"MS Ewer","year":"2009","unstructured":"Ewer\u00a0MS, Gluck\u00a0S. A woman\u2019s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115(9):1813\u201326.","journal-title":"Cancer"},{"key":"2031_CR65","doi-asserted-by":"publisher","first-page":"k3845","DOI":"10.1136\/bmj.k3845","volume":"363","author":"A Matthews","year":"2018","unstructured":"Matthews\u00a0A, Stanway\u00a0S, Farmer\u00a0RE, Strongman\u00a0H, Thomas\u00a0S, Lyon\u00a0AR, et\u00a0al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.","journal-title":"BMJ"},{"issue":"22","key":"2031_CR66","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","volume":"104","author":"V Grouthier","year":"2018","unstructured":"Grouthier\u00a0V, Lebrun-Vignes\u00a0B, Glazer\u00a0AM, Touraine\u00a0P, Funck-Brentano\u00a0C, Pariente\u00a0A, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018;104(22):1859\u201363.","journal-title":"Heart"},{"issue":"5","key":"2031_CR67","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/cvr\/cvz020","volume":"115","author":"M Barber","year":"2019","unstructured":"Barber\u00a0M, Nguyen\u00a0LS, Wassermann\u00a0J, Spano\u00a0JP, Funck-Brentano\u00a0C, Salem\u00a0JE. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115(5):878\u201394.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"2031_CR68","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JOP.18.00178","volume":"14","author":"D Gupta","year":"2018","unstructured":"Gupta\u00a0D, Lee Chuy\u00a0K, Yang\u00a0JC, Bates\u00a0M, Lombardo\u00a0M, Steingart\u00a0RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J\u00a0Oncol Pract. 2018;14(10):580\u20137.","journal-title":"J Oncol Pract"},{"issue":"5","key":"2031_CR69","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen\u00a0PL, Alibhai\u00a0SM, Basaria\u00a0S, D\u2019Amico\u00a0AV, Kantoff\u00a0PW, Keating\u00a0NL, et\u00a0al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"key":"2031_CR70","first-page":"e55","volume":"40","author":"JR Hu","year":"2020","unstructured":"Hu\u00a0JR, Duncan\u00a0MS, Morgans\u00a0AK, Brown\u00a0JD, Meijers\u00a0WC, Freiberg\u00a0MS, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40:e55\u2013e64.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2031_CR71","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque\u00a0R, UlcickasYood\u00a0M, Xu\u00a0X, Cassidy-Bushrow\u00a0AE, Tsai\u00a0HT, Keating\u00a0NL, et al. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a\u00a0prospective cohort study. Br J Cancer. 2017;117(8):1233\u201340.","journal-title":"Br J Cancer"},{"issue":"16","key":"2031_CR72","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes\u00a0RD, Higano\u00a0CS, Slovin\u00a0SF, Nelson\u00a0AJ, Bigelow\u00a0R, S\u00f8rensen\u00a0PS, et\u00a0al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295\u2013307.","journal-title":"Circulation"},{"key":"2031_CR73","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","volume":"104","author":"SJH Dobbin","year":"2018","unstructured":"Dobbin\u00a0SJH, Cameron\u00a0AC, Petrie\u00a0MC, Jones\u00a0RJ, Touyz\u00a0RM, Lang\u00a0NN. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018;104:1995\u20132002.","journal-title":"Heart"},{"issue":"10","key":"2031_CR74","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","volume":"128","author":"VS Hahn","year":"2021","unstructured":"Hahn\u00a0VS, Zhang\u00a0KW, Sun\u00a0L, Narayan\u00a0V, Lenihan\u00a0DJ, Ky\u00a0B. Heart failure with targeted cancer therapies: mechanisms and cardioprotection. Circ Res. 2021;128(10):1576\u201393.","journal-title":"Circ Res"},{"key":"2031_CR75","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","volume":"11","author":"M Chaar","year":"2018","unstructured":"Chaar\u00a0M, Kamta\u00a0J, Ait-Oudhia\u00a0S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther. 2018;11:6227\u201337.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"2031_CR76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz\u00a0RM, Herrmann\u00a0SMS, Herrmann\u00a0J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J\u00a0Am Soc Hypertens. 2018;12(6):409\u201325.","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"2031_CR77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","volume":"41","author":"MD Wu","year":"2021","unstructured":"Wu\u00a0MD, Moslehi\u00a0JJ, Lindner\u00a0JR. Arterial thrombotic complications of tyrosine kinase inhibitors. Arterioscler Thromb Vasc Biol. 2021;41(1):3\u201310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2031_CR78","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1442-2042.2012.03033.x","volume":"19","author":"M Schmidinger","year":"2012","unstructured":"Schmidinger\u00a0M, Bergler-Klein\u00a0J. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. Int J Urol. 2012;19:796\u2013804.","journal-title":"Int J Urol"},{"issue":"8","key":"2031_CR79","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.7150\/thno.49837","volume":"11","author":"J Sourdon","year":"2021","unstructured":"Sourdon\u00a0J, Facchin\u00a0C, Certain\u00a0A, Viel\u00a0T, Robin\u00a0B, Lager\u00a0F, et al. Sunitinib-induced cardiac hypertrophy and the endothelin axis. Theranostics. 2021;11(8):3830\u20138.","journal-title":"Theranostics"},{"issue":"8","key":"2031_CR80","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","volume":"147","author":"W Hou","year":"2021","unstructured":"Hou\u00a0W, Ding\u00a0M, Li\u00a0X, Zhou\u00a0X, Zhu\u00a0Q, Varela-Ramirez\u00a0A, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a\u00a0Bayesian network analysis of randomized controlled trials. J\u00a0Cancer Res Clin Oncol. 2021;147(8):2407\u201320.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2031_CR81","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","volume":"7","author":"J Alexandre","year":"2021","unstructured":"Alexandre\u00a0J, Salem\u00a0JE, Moslehi\u00a0J, Sassier\u00a0M, Ropert\u00a0C, Cautela\u00a0J, et\u00a0al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312\u201320.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"13","key":"2031_CR82","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem\u00a0JE, Manouchehri\u00a0A, Bretagne\u00a0M, Lebrun-Vignes\u00a0B, Groarke\u00a0JD, Johnson\u00a0DB, et al. Cardiovascular toxicities associated with Ibrutinib. J\u00a0Am Coll Cardiol. 2019;74(13):1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"2031_CR83","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jacc.2019.07.057","volume":"74","author":"J Bergler-Klein","year":"2019","unstructured":"Bergler-Klein\u00a0J. Real-life insight into ibrutinib cardiovascular events: defining the loose ends. J\u00a0Am Coll Cardiol. 2019;74:1679\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2031_CR84","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown\u00a0JR, Moslehi\u00a0J, O\u2019Brien\u00a0S, Ghia\u00a0P, Hillmen\u00a0P, Cymbalista\u00a0F, et\u00a0al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805.","journal-title":"Haematologica"},{"key":"2031_CR85","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","volume":"29","author":"A Guha","year":"2019","unstructured":"Guha\u00a0A, Armanious\u00a0M, Fradley\u00a0MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019;29:29\u201339.","journal-title":"Trends Cardiovasc Med"},{"issue":"11","key":"2031_CR86","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","volume":"114","author":"JM Duran","year":"2014","unstructured":"Duran\u00a0JM, Makarewich\u00a0CA, Trappanese\u00a0D, Gross\u00a0P, Husain\u00a0S, Dunn\u00a0J, et\u00a0al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 2014;114(11):1700\u201312.","journal-title":"Circ Res"},{"issue":"1","key":"2031_CR87","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/s41598-018-23630-w","volume":"8","author":"C Schneider","year":"2018","unstructured":"Schneider\u00a0C, Wallner\u00a0M, Kolesnik\u00a0E, Herbst\u00a0V, M\u00e4chler\u00a0H, Pichler\u00a0M, et al. The anti-cancer multikinase inhibitor sorafenib impairs cardiac contractility by reducing phospholamban phosphorylation and sarcoplasmic calcium transients. Sci Rep. 2018;8(1):5295.","journal-title":"Sci Rep"},{"issue":"10","key":"2031_CR88","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1464-410X.2012.11134.x","volume":"110","author":"PP Rainer","year":"2012","unstructured":"Rainer\u00a0PP, Doleschal\u00a0B, Kirk\u00a0JA, Sivakumaran\u00a0V, Saad\u00a0Z, Groschner\u00a0K, et al. Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes. BJU Int. 2012;110(10):1455\u201362.","journal-title":"BJU Int"},{"issue":"2","key":"2031_CR89","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma\u00a0P, Allison\u00a0JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.","journal-title":"Cell"},{"issue":"6382","key":"2031_CR90","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas\u00a0A, Wolchok\u00a0JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"1","key":"2031_CR91","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin\u00a0J, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R, Grob\u00a0JJ, Cowey\u00a0CL, Lao\u00a0CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N\u00a0Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"2031_CR92","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3390\/cancers13061430","volume":"13","author":"J Steininger","year":"2021","unstructured":"Steininger\u00a0J, Gellrich\u00a0FF, Schulz\u00a0A, Westphal\u00a0D, Beissert\u00a0S, Meier\u00a0F. Systemic therapy of metastatic melanoma: on the road to cure. Cancers (Basel). 2021;13(6):1430.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2031_CR93","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei\u00a0H, Gettinger\u00a0S, Vokes\u00a0EE, Chow\u00a0LQM, Burgio\u00a0MA, de Castro Carpeno\u00a0J, et al. Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J\u00a0Clin Oncol. 2021;39(7):723\u201333.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2031_CR94","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson\u00a0DB, Balko\u00a0JM, Compton\u00a0ML, Chalkias\u00a0S, Gorham\u00a0J, Xu\u00a0Y, et\u00a0al. Fulminant myocarditis with combination immune checkpoint blockade. N\u00a0Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"10124","key":"2031_CR95","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi\u00a0JJ, Salem\u00a0JE, Sosman\u00a0JA, Lebrun-Vignes\u00a0B, Johnson\u00a0DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.","journal-title":"Lancet"},{"key":"2031_CR96","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood\u00a0SS, Fradley\u00a0MG, Cohen\u00a0JV, Nohria\u00a0A, Reynolds\u00a0KL, Heinzerling\u00a0LM, et\u00a0al. Myocarditis in patients treated with immune checkpoint inhibitors. J\u00a0Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2031_CR97","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","volume":"42","author":"M D\u2019Souza","year":"2021","unstructured":"D\u2019Souza\u00a0M, Nielsen\u00a0D, Svane\u00a0IM, Iversen\u00a0K, Rasmussen\u00a0PV, Madelaire\u00a0C, et\u00a0al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a\u00a0nationwide Danish study. Eur Heart\u00a0J. 2021;42(16):1621\u201331.","journal-title":"Eur Heart J"},{"key":"2031_CR98","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"36","author":"M Escudier","year":"2017","unstructured":"Escudier\u00a0M, Cautela\u00a0J, Malissen\u00a0N, Ancedy\u00a0Y, Orabona\u00a0M, Pinto\u00a0J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;36:2085\u20137.","journal-title":"Circulation"},{"issue":"2","key":"2031_CR99","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas\u00a0N, Lopez-Mattei\u00a0J, Durand\u00a0JB, Iliescu\u00a0C, Deswal\u00a0A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J\u00a0Am Heart Assoc. 2020;9(2):e13757.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"2031_CR100","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu\u00a0JR, Florido\u00a0R, Lipson\u00a0EJ, Naidoo\u00a0J, Ardehali\u00a0R, Tocchetti\u00a0CG, et\u00a0al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854\u201368.","journal-title":"Cardiovasc Res"},{"issue":"20","key":"2031_CR101","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/cancers13205218","volume":"13","author":"W Shalata","year":"2021","unstructured":"Shalata\u00a0W, Abu-Salman\u00a0A, Steckbeck\u00a0R, Mathew Jacob\u00a0B, Massalha\u00a0I, Yakobson\u00a0A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021;13(20):5218.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2031_CR102","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.esmoop.2021.100216","volume":"6","author":"D Delombaerde","year":"2021","unstructured":"Delombaerde\u00a0D, Vervloet\u00a0D, Franssen\u00a0C, Croes\u00a0L, Gremonprez\u00a0F, Prenen\u00a0H, et\u00a0al. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open. 2021;6(4):100216.","journal-title":"ESMO Open"},{"issue":"12","key":"2031_CR103","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak\u00a0R, Katel\u00a0A, Massarelli\u00a0E, Villaflor\u00a0VM, Sun\u00a0V, Salgia\u00a0R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26(12):1052\u201361.","journal-title":"Oncologist"},{"issue":"2","key":"2031_CR104","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca\u00a0MP, Olenchock\u00a0BA, Salem\u00a0JE, Wiviott\u00a0SD, Ederhy\u00a0S, Cohen\u00a0A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"issue":"12","key":"2031_CR105","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan\u00a0P, Zhang\u00a0L, Zafar\u00a0A, Drobni\u00a0ZD, Mahmood\u00a0SS, Cabral\u00a0M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated Myocarditis. J\u00a0Am Coll Cardiol. 2021;77(12):1503\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2031_CR106","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang\u00a0L, Awadalla\u00a0M, Mahmood\u00a0SS, Nohria\u00a0A, Hassan\u00a0MZO, Thuny\u00a0F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart\u00a0J. 2020;41(18):1733\u201343.","journal-title":"Eur Heart J"},{"issue":"10","key":"2031_CR107","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas\u00a0NL, Segura\u00a0A, Lelenwa\u00a0L, Siddiqui\u00a0BA, Subudhi\u00a0SK, Lopez-Mattei\u00a0J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2031_CR108","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem\u00a0JE, Manouchehri\u00a0A, Moey\u00a0M, et\u00a0al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"18","key":"2031_CR109","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","volume":"144","author":"JR Power","year":"2021","unstructured":"Power\u00a0JR, Alexandre\u00a0J, Choudhary\u00a0A, Ozbay\u00a0B, Hayek\u00a0S, Asnani\u00a0A, et al. International ICI-myocarditis registry. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation. 2021;144(18):1521\u20133.","journal-title":"Circulation"},{"issue":"11","key":"2031_CR110","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann\u00a0LH, Cautela\u00a0J, Palaskas\u00a0N, Baik\u00a0AH, Meijers\u00a0WC, Allenbach\u00a0Y, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 2021;6(11):1329\u201337.","journal-title":"JAMA Cardiol"},{"issue":"17","key":"2031_CR111","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer\u00a0JR, Lacchetti\u00a0C, Schneider\u00a0BJ, et al. National comprehensive cancer network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J\u00a0Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2031_CR112","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem\u00a0JE, Allenbach\u00a0Y, Vozy\u00a0A, Brechot\u00a0N, Johnson\u00a0DB, Moslehi\u00a0JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N\u00a0Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"key":"2031_CR113","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei\u00a0SC, Meijers\u00a0WC, Axelrod\u00a0ML, Anang\u00a0NAAS, Screever\u00a0EM, Wescott\u00a0EC, et al. A genetic mouse model recapitulates immune checkpoint inhibitor\u2013associated myocarditis and supports a\u00a0mechanism-based therapeutic intervention. Cancer Discov. 2021;11:614\u201325.","journal-title":"Cancer Discov"},{"issue":"9","key":"2031_CR114","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms\u00a0J, Prior\u00a0JO, Peters\u00a0S, Obeid\u00a0M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31(9):1273\u20135.","journal-title":"Ann Oncol"},{"issue":"8","key":"2031_CR115","doi-asserted-by":"publisher","first-page":"e002303","DOI":"10.1136\/jitc-2020-002303","volume":"9","author":"JE Brammer","year":"2021","unstructured":"Brammer\u00a0JE, Braunstein\u00a0Z, Katapadi\u00a0A, Porter\u00a0K, Biersmith\u00a0M, Guha\u00a0A, et al. Early toxicity and clinical outcomes after chimeric antigen receptor T\u2011cell (CAR-T) therapy for lymphoma. J\u00a0Immunother Cancer. 2021;9(8):e2303.","journal-title":"J Immunother Cancer"},{"issue":"21","key":"2031_CR116","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","volume":"107","author":"AF Stein-Merlob","year":"2021","unstructured":"Stein-Merlob\u00a0AF, Rothberg\u00a0MV, Ribas\u00a0A, Yang\u00a0EH. Cardiotoxicities of novel cancer immunotherapies. Heart. 2021;107(21):1694\u2013703.","journal-title":"Heart"},{"issue":"18","key":"2031_CR117","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman\u00a0A, Maor\u00a0E, Bomze\u00a0D, Liu\u00a0JE, Herrmann\u00a0J, Fein\u00a0J, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T\u2011cell therapy. J\u00a0Am Coll Cardiol. 2021;78(18):1800\u201313.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2031_CR118","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"HM Chang","year":"2017","unstructured":"Chang\u00a0HM, Moudgil\u00a0R, Scarabelli\u00a0T, Okwuosa\u00a0TM, Yeh\u00a0ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J\u00a0Am Coll Cardiol. 2017;70(20):2536\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2031_CR119","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon\u00a0D, Eiermann\u00a0W, Robert\u00a0N, Pienkowski\u00a0T, Martin\u00a0M, Press\u00a0M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N\u00a0Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"12","key":"2031_CR120","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano\u00a0JL, Gottfridsson\u00a0C, Asteggiano\u00a0R, Atar\u00a0D, Badimon\u00a0L, Bax\u00a0JJ, et\u00a0al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290\u2013309.","journal-title":"Eur J Heart Fail"},{"key":"2031_CR121","doi-asserted-by":"publisher","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara\u00a0JD, Kaur\u00a0J, Khodadadi\u00a0R, Rehman\u00a0M, Lobo\u00a0R, Chakrabarti\u00a0S, et al. 5\u2011fluorouracil and cardiotoxicity: a\u00a0review. Ther Adv Med Oncol. 2018;10:1758835918780140.","journal-title":"Ther Adv Med Oncol"},{"key":"2031_CR122","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel\u00a0DS, Dimopoulos\u00a0MA, Ludwig\u00a0H, Facon\u00a0T, Goldschmidt\u00a0H, Jakubowiak\u00a0A, et\u00a0al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J\u00a0Clin Oncol. 2018;36:728\u201334.","journal-title":"J Clin Oncol"},{"key":"2031_CR123","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","volume":"21","author":"EW Grandin","year":"2015","unstructured":"Grandin\u00a0EW, Ky\u00a0B, Cornell\u00a0RF, Carver\u00a0J, Lenihan\u00a0DJ. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J\u00a0Card Fail. 2015;21:138\u201344.","journal-title":"J Card Fail"},{"issue":"22","key":"2031_CR124","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell\u00a0RF, Ky\u00a0B, Weiss\u00a0BM, Dahm\u00a0CN, Gupta\u00a0DK, Du\u00a0L, et\u00a0al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J\u00a0Clin Oncol. 2019;37(22):1946\u201355.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2031_CR125","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.24599","volume":"92","author":"JC Reneau","year":"2017","unstructured":"Reneau\u00a0JC, Asante\u00a0D, van Houten\u00a0H, Sangaralingham\u00a0LR, Buadi\u00a0FK, Lerman\u00a0A, et\u00a0al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: a propensity matched study of 1,790\u00a0patients. Am J Hematol. 2017;92(2):E15\u2013E7.","journal-title":"Am J Hematol"},{"issue":"10","key":"2031_CR126","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar\u00a0SK, Jacobus\u00a0SJ, Cohen\u00a0AD, Weiss\u00a0M, Callander\u00a0N, Singh\u00a0AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a\u00a0multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317\u201330.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2031_CR127","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/ehjacc\/zuab056","volume":"10","author":"SA Gevaert","year":"2021","unstructured":"Gevaert\u00a0SA, Halvorsen\u00a0S, Sinnaeve\u00a0PR, Sambola\u00a0A, Gulati\u00a0G, Lancellotti\u00a0P, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a\u00a0consensus document of the acute cardiovascular care (ACVC) association and the ESC council of cardio-oncology-part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care. 2021;10(8):947\u201359.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"10226","key":"2031_CR128","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring\u00a0LM, Wander\u00a0SA, Andre\u00a0F, Moy\u00a0B, Turner\u00a0NC, Bardia\u00a0A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"3","key":"2031_CR129","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.hemonc.2020.03.001","volume":"14","author":"S Ball","year":"2021","unstructured":"Ball\u00a0S, Swarup\u00a0S, Sultan\u00a0A, Thein\u00a0KZ. Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials. Hematol Oncol Stem Cell Ther. 2021;14(3):260\u20132.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"36","key":"2031_CR130","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, Gardner\u00a0RS, Baumbach\u00a0A, B\u00f6hm\u00a0M, et\u00a0al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"8","key":"2031_CR131","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin\u00a0E, Mackey\u00a0JR, Koshman\u00a0S, Jassal\u00a0D, Pitz\u00a0M, Haykowsky\u00a0MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J\u00a0Clin Oncol. 2017;35(8):870\u20137.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2031_CR132","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati\u00a0G, Heck\u00a0SL, Ree\u00a0AH, Hoffmann\u00a0P, Schulz-Menger\u00a0J, Fagerland\u00a0MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a\u00a02 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart\u00a0J. 2016;37(21):1671\u201380.","journal-title":"Eur Heart J"},{"issue":"1","key":"2031_CR133","first-page":"24","volume":"6","author":"V Gregorietti","year":"2020","unstructured":"Gregorietti\u00a0V, Fernandez\u00a0TL, Costa\u00a0D, Chahla\u00a0EO, Daniele\u00a0AJ. Use of sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6(1):24.","journal-title":"Cardiooncology"},{"issue":"1","key":"2031_CR134","first-page":"35","volume":"7","author":"MK Frey","year":"2021","unstructured":"Frey\u00a0MK, Arfsten\u00a0H, Pavo\u00a0N, Han\u00a0E, Kastl\u00a0S, H\u00fclsmann\u00a0M, et al. Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data. Cardiooncology. 2021;7(1):35.","journal-title":"Cardiooncology"},{"key":"2031_CR135","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12254-021-00766-6","volume":"15","author":"J Bergler-Klein","year":"2022","unstructured":"Bergler-Klein\u00a0J. Cardiotoxicity\u2014current recommendations of prevention and treatment. memo \u2013\u00a0Magazine of European Medical Oncology. 2022;15:67\u201371.","journal-title":"memo \u2013\u00a0Magazine of European Medical Oncology"},{"key":"2031_CR136","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","volume":"61","author":"C Jaworski","year":"2013","unstructured":"Jaworski\u00a0C, Mariani\u00a0JA, Wheeler\u00a0G, Kaye\u00a0DM. Cardiac complications of thoracic irradiation. J\u00a0Am Coll Cardiol. 2013;61:2319\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2031_CR137","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","volume":"26","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti\u00a0P, Nkomo\u00a0VT, Badano\u00a0LP, Bergler-Klein\u00a0J, Bogaert\u00a0J, Davin\u00a0L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a\u00a0report from the European association of cardiovascular imaging and the American society of echocardiography. J\u00a0Am Soc Echocardiogr. 2013;26(9):1013\u201332.","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"2031_CR138","first-page":"360","volume":"3","author":"JD Mitchell","year":"2021","unstructured":"Mitchell\u00a0JD, Cehic\u00a0DA, Morgia\u00a0M, Bergrom\u00a0C, Toohey\u00a0J, Guerrero\u00a0PA, et al. Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society. J\u00a0Am Coll Cardiol. 2021;3(3):360\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2031_CR139","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","volume":"34","author":"FA van Nimwegen","year":"2016","unstructured":"van Nimwegen\u00a0FA, Schaapveld\u00a0M, Cutter\u00a0DJ, Janus\u00a0CP, Krol\u00a0AD, Hauptmann\u00a0M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J\u00a0Clin Oncol. 2016;34(3):235\u201343.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2031_CR140","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby\u00a0SC, Ewertz\u00a0M, McGale\u00a0P, Bennet\u00a0AM, Blom-Goldman\u00a0U, Br\u00f8nnum\u00a0D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N\u00a0Engl J Med. 2013;368(11):987\u201398.","journal-title":"N Engl J Med"},{"issue":"5","key":"2031_CR141","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.ijrobp.2010.01.004","volume":"79","author":"K Erven","year":"2011","unstructured":"Erven\u00a0K, Jurcut\u00a0R, Weltens\u00a0C, Giusca\u00a0S, Ector\u00a0J, Wildiers\u00a0H, et\u00a0al. Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011;79(5):1444\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"2031_CR142","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1161\/CIRCULATIONAHA.120.046575","volume":"142","author":"AN Dunn","year":"2020","unstructured":"Dunn\u00a0AN, Donnellan\u00a0E, Johnston\u00a0DR, Alashi\u00a0A, Reed\u00a0GW, Jellis\u00a0C, et al. Long-term outcomes of patients with mediastinal radiation-associated coronary artery disease undergoing coronary revascularization with percutaneous coronary intervention and coronary artery bypass grafting. Circulation. 2020;142(14):1399\u2013401.","journal-title":"Circulation"},{"issue":"4","key":"2031_CR143","doi-asserted-by":"publisher","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","volume":"107","author":"DJ Cutter","year":"2015","unstructured":"Cutter\u00a0DJ, Schaapveld\u00a0M, Darby\u00a0SC, Hauptmann\u00a0M, van Nimwegen\u00a0FA, Krol\u00a0AD, et\u00a0al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J\u00a0Natl Cancer Inst. 2015;107(4):djv8.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2031_CR144","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","volume":"76","author":"G Gagliardi","year":"2010","unstructured":"Gagliardi\u00a0G, Constine\u00a0LS, Moiseenko\u00a0V, Correa\u00a0C, Pierce\u00a0LJ, Allen\u00a0AM, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3):S77\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2031_CR145","first-page":"136","volume":"3","author":"J Bergler-Klein","year":"2019","unstructured":"Bergler-Klein\u00a0J, Badr Eslam\u00a0R, Schneider\u00a0M, Frey\u00a0M, Gy\u00f6ngy\u00f6si\u00a0M, Binder\u00a0T. Radiation induced valve disease and cardiotoxicity induced heart failure is frequent. Heart. 2019;3(1):136\u2013136.","journal-title":"Heart"},{"key":"2031_CR146","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ccd.21681","volume":"72","author":"JA Jurado","year":"2008","unstructured":"Jurado\u00a0JA, Bashir\u00a0R, Burket\u00a0MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72:563\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"2031_CR147","first-page":"363","volume":"2","author":"JM Leerink","year":"2020","unstructured":"Leerink\u00a0JM, de Baat\u00a0EC, Feijen\u00a0EAM, Bellersen\u00a0L, van Dalen\u00a0EC, Grotenhuis\u00a0HB, et al. Cardiac disease in childhood cancer survivors: risk prediction, prevention, and surveillance: JACC cardiooncology state-of-the-art review. J\u00a0Am Coll Cardiol. 2020;2(3):363\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"2031_CR148","doi-asserted-by":"publisher","first-page":"i4351","DOI":"10.1136\/bmj.i4351","volume":"354","author":"MM Fidler","year":"2016","unstructured":"Fidler\u00a0MM, Reulen\u00a0RC, Winter\u00a0DL, Kelly\u00a0J, Jenkinson\u00a0HC, Skinner\u00a0R, et\u00a0al. Long term cause specific mortality among 34 489 five year survivors of childhood cancer in Great Britain: population based cohort study. BMJ. 2016;354:i4351.","journal-title":"BMJ"},{"issue":"10","key":"2031_CR149","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.116.024811","volume":"135","author":"MM Fidler","year":"2017","unstructured":"Fidler\u00a0MM, Reulen\u00a0RC, Henson\u00a0K, Kelly\u00a0J, Cutter\u00a0D, Levitt\u00a0GA, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in great britain. Circulation. 2017;135(10):951\u201363.","journal-title":"Circulation"},{"issue":"2","key":"2031_CR150","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/bmt.2016.203","volume":"52","author":"Z DeFilipp","year":"2017","unstructured":"DeFilipp\u00a0Z, Duarte\u00a0RF, Snowden\u00a0JA, Majhail\u00a0NS, Greenfield\u00a0DM, Miranda\u00a0JL, et\u00a0al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017;52(2):173\u201382.","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2031_CR151","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/eurheartj\/ehy026","volume":"39","author":"J Faber","year":"2018","unstructured":"Faber\u00a0J, Wingerter\u00a0A, Neu\u00a0MA, Henninger\u00a0N, Eckerle\u00a0S, M\u00fcnzel\u00a0T, et al. Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study. Eur Heart\u00a0J. 2018;39(17):1555\u201362.","journal-title":"Eur Heart J"},{"issue":"5","key":"2031_CR152","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ijc.29468","volume":"137","author":"T Gudmundsdottir","year":"2015","unstructured":"Gudmundsdottir\u00a0T, Winther\u00a0JF, de Fine Licht\u00a0S, Bonnesen\u00a0TG, Asdahl\u00a0PH, Tryggvadottir\u00a0L, et al. Cardiovascular disease in adult life after childhood cancer in Scandinavia: a population-based cohort study of 32,308 one-year survivors. Int J Cancer. 2015;137(5):1176\u201386.","journal-title":"Int J Cancer"},{"issue":"3","key":"2031_CR153","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","volume":"16","author":"SH Armenian","year":"2015","unstructured":"Armenian\u00a0SH, Hudson\u00a0MM, Mulder\u00a0RL, Chen\u00a0MH, Constine\u00a0LS, Dwyer\u00a0M, et\u00a0al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a\u00a0report from the international late effects of childhood cancer guideline harmonization group. Lancet Oncol. 2015;16(3):e123\u201336.","journal-title":"Lancet Oncol"},{"key":"2031_CR154","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2021.06.021","volume":"156","author":"EC van Dalen","year":"2021","unstructured":"van Dalen\u00a0EC, Mulder\u00a0RL, Suh\u00a0E, Ehrhardt\u00a0MJ, Aune\u00a0GJ, Bardi\u00a0E, et\u00a0al. Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the international late effects of childhood cancer guideline harmonization group. Eur J Cancer. 2021;156:127\u201337.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2031_CR155","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/heartjnl-2018-313634","volume":"105","author":"JM Leerink","year":"2019","unstructured":"Leerink\u00a0JM, Verkleij\u00a0SJ, Feijen\u00a0EAM, Mavinkurve-Groothuis\u00a0AMC, Pourier\u00a0MS, Ylanen\u00a0K, et al. Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a\u00a0systematic review. Heart. 2019;105(3):210\u20136.","journal-title":"Heart"},{"issue":"3","key":"2031_CR156","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cncr.33292","volume":"127","author":"SB Dixon","year":"2021","unstructured":"Dixon\u00a0SB, Howell\u00a0CR, Lu\u00a0L, Plana\u00a0JC, Joshi\u00a0VM, Luepker\u00a0RV, et\u00a0al. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: a report from the St. Jude lifetime cohort. Cancer. 2021;127(3):458\u201366.","journal-title":"Cancer"},{"key":"2031_CR157","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-01028-4","author":"R Merkx","year":"2021","unstructured":"Merkx\u00a0R, Leerink\u00a0JM, de Baat\u00a0EC, Feijen\u00a0EAM, Kok\u00a0WEM, Mavinkurve-Groothuis\u00a0AMC, et al. Asymptomatic systolic dysfunction on contemporary echocardiography in anthracycline-treated long-term childhood cancer survivors: a\u00a0systematic review. J\u00a0Cancer Surviv. 2021; https:\/\/doi.org\/10.1007\/s11764-021-01028-4.","journal-title":"J Cancer Surviv"},{"key":"2031_CR158","first-page":"CD008011","volume":"8","author":"DK Cheuk","year":"2016","unstructured":"Cheuk\u00a0DK, Sieswerda\u00a0E, van Dalen\u00a0EC, Postma\u00a0A, Kremer\u00a0LC. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;8:CD8011.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2031_CR159","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2012.46.6854","volume":"31","author":"MS McCabe","year":"2013","unstructured":"McCabe\u00a0MS, Bhatia\u00a0S, Oeffinger\u00a0KC, Reaman\u00a0GH, Tyne\u00a0C, Wollins\u00a0DS, et al. American society of clinical oncology statement: achieving high-quality cancer survivorship care. J\u00a0Clin Oncol. 2013;31(5):631\u201340.","journal-title":"J Clin Oncol"},{"key":"2031_CR160","first-page":"CD008465","volume":"8","author":"SI Mishra","year":"2012","unstructured":"Mishra\u00a0SI, Scherer\u00a0RW, Snyder\u00a0C, Geigle\u00a0PM, Berlanstein\u00a0DR, Topaloglu\u00a0O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD8465.","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2031_CR161","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1200\/JCO.2017.77.5809","volume":"36","author":"JM Scott","year":"2018","unstructured":"Scott\u00a0JM, Zabor\u00a0EC, Schwitzer\u00a0E, Koelwyn\u00a0GJ, Adams\u00a0SC, Nilsen\u00a0TS, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J\u00a0Clin Oncol. 2018;36(22):2297\u2013305.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2031_CR162","first-page":"41","volume":"1","author":"TM Okwuosa","year":"2019","unstructured":"Okwuosa\u00a0TM, Ray\u00a0RM, Palomo\u00a0A, Foraker\u00a0RE, Johnson\u00a0L, Paskett\u00a0ED, et al. Pre-diagnosis exercise and cardiovascular events in primary breast cancer: women\u2019s health initiative. J\u00a0Am Coll Cardiol. 2019;1(1):41\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2031_CR163","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","volume":"137","author":"JM Scott","year":"2018","unstructured":"Scott\u00a0JM, Nilsen\u00a0TS, Gupta\u00a0D, Jones\u00a0LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176\u201391.","journal-title":"Circulation"},{"key":"2031_CR164","unstructured":"Ellahham SH. Exercise before, during, and after cancer therapy. Expert analysis, American college of cardiology. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/12\/04\/08\/22\/exercise-before-during-and-after-cancer-therapy. Accessed 22\u00a0Dec 2021."},{"issue":"21","key":"2031_CR165","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","volume":"139","author":"SC Gilchrist","year":"2019","unstructured":"Gilchrist\u00a0SC, Barac\u00a0A, Ades\u00a0PA, Alfano\u00a0CM, Franklin\u00a0BA, Jones\u00a0LW, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American heart association. Circulation. 2019;139(21):e997\u2013e1012.","journal-title":"Circulation"},{"issue":"1","key":"2031_CR166","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12872-021-01970-2","volume":"21","author":"E D\u00edaz-Balboa","year":"2021","unstructured":"D\u00edaz-Balboa\u00a0E, Gonz\u00e1lez-Salvado\u00a0V, Rodr\u00edguez-Romero\u00a0B, Mart\u00ednez-Monzon\u00eds\u00a0A, Pedreira-P\u00e9rez\u00a0M, Palacios-Ozores\u00a0P, et al. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol. BMC Cardiovasc Disord. 2021;21(1):165.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"2031_CR167","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ejhf.1165","volume":"20","author":"P Ameri","year":"2018","unstructured":"Ameri\u00a0P, Canepa\u00a0M, Anker\u00a0MS, Belenkov\u00a0Y, Bergler-Klein\u00a0J, Cohen-Solal\u00a0A, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018;20(5):879\u201387.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"2031_CR168","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","volume":"40","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti\u00a0P, Suter\u00a0TM, L\u00f3pez-Fern\u00e1ndez\u00a0T, Galderisi\u00a0M, Lyon\u00a0AR, Van der Meer\u00a0P, et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart\u00a0J. 2019;40(22):1756\u201363.","journal-title":"Eur Heart J"},{"key":"2031_CR169","unstructured":"European Society of Cardiology. Cardio-oncology in Austria. 2022. https:\/\/www.escardio.org\/Councils\/council-of-cardio-oncology\/cardio-oncology-in-austria. Accessed 22\u00a0Dec 2021."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-022-02031-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T18:39:51Z","timestamp":1727116791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-022-02031-0"}},"subtitle":["Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology"],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":169,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1007\/s00508-022-02031-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Bergler-Klein, P.P.\u00a0Rainer, M.\u00a0Wallner, M.-M.\u00a0Zaruba, J.\u00a0D\u00f6rler, A. B\u00f6hmer, T.\u00a0Buchacher, M.\u00a0Frey, C. Adlbrecht, R.\u00a0Bartsch, M.\u00a0Gy\u00f6ngy\u00f6si and U.-M.\u00a0F\u00fcrst declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}